FAQ · Last reviewed 2026-05-16
Frequently asked questions
Answers to the most common questions, with direct reference to the dossier where the topic is treated in depth.
The Dutch Protocol is a phased clinical pathway for adolescents with persistent gender dysphoria, developed in the Netherlands (according to the Cass Review by Peggy Cohen-Kettenis, founder of the Utrecht clinic; source). It combines psychological assessment, puberty suppression (GnRHa) and, from age 16, cross-sex hormones (source), with surgery later (source). See /protocol/definition/.
According to the Cass Review, the Dutch services for children and young people with gender incongruence started in 1987; the protocol was developed by Peggy Cohen-Kettenis, founder of the Utrecht clinic (source). The first publication followed in 1998 (Cohen-Kettenis & van Goozen): a case report of one patient who started puberty suppression at age 13 (source). The protocol was further elaborated in 2006 (Delemarre-van de Waal & Cohen-Kettenis). See /protocol/origins/ and /timeline/.
GnRHa (gonadotrophin-releasing hormone agonist) suppresses endogenous puberty. According to the Cass Review, most guidelines emphasise full reversibility as a justification, while pointing to possible adverse effects on bone health and uncertainty about cognitive development (source). The University of York systematic review for the Cass Review found that bone density decreases during suppression; for the effects on cognitive development, cardiometabolic risk and fertility the evidence is insufficient or inconsistent (source). See /protocol/the-three-phases/ and /evaluations/cass-review-2024/.
According to the abstract of the 2006 protocol article, puberty suppression (GnRHa) starts at breast stages B2-3 and genital stages G3-4, and cross-sex hormones can be added from age 16 (source). The Cass Review gives a minimum age of 12 for the original Dutch protocol and writes that pausing puberty at Tanner stage 2 started in the Netherlands (source). According to the same review, the requirement to wait until age 12 has been removed from some guidelines, for example WPATH 8 (source). See /protocol/age-criteria/.
The original core publications concern 70 (de Vries 2011) and 55 (de Vries 2014) adolescents (source, source). A later cohort study by Amsterdam UMC (Van der Loos 2022) included 720 people who had started puberty suppression before age 18 and then hormones; of them, 98 percent (704) still had a prescription for hormones at the end of data collection on 31 December 2018 (source). See /studies/sample-size-and-attrition/.
The fading of cross-gender identification in children before or during puberty. Follow-up studies of clinic-referred children find different persistence rates: 12 percent of 139 boys in Singh 2021 (source), 27 percent in Wallien and Cohen-Kettenis 2008, in which 43 percent were no longer gender dysphoric and 30 percent could not be traced (source), and 37 percent in Steensma 2013 (source). In the Olson 2022 study of 317 children who had already socially transitioned, 94 percent identified as binary transgender on average five years after that transition (source). See /debate/desistance-research/.
How often people detransition or regret treatment is not known. The Cass Review concludes that the percentage who detransition after hormone treatment is unknown because long-term follow-up is lacking (source). Dutch research cited by the Gezondheidsraad (2026) shows that 0 to 3.5 percent stop hormone treatment started as a minor, and no cases of regret were found in those studies; according to the council, however, no definitive conclusions can be drawn about regret because of the mostly short follow-up and the substantial attrition in studies (source). See /debate/detransition-research/.
The British Cass Review (April 2024) calls the research on care for young people with gender incongruence "an area of remarkably weak evidence". Cass recommends that puberty blockers be given only within a research trial, advises "extreme caution" with masculinising or feminising hormones from age 16, and wants every child and young person referred to NHS gender services to be screened for neurodevelopmental conditions such as autism (source). See /evaluations/cass-review-2024/.
Sweden (SBU 2022, Socialstyrelsen 2022), Norway (Ukom 2023) and Finland (COHERE 2020) have revised their policy (source, source, source). In the UK, NICE (2020), the Cass Review (2024) and a decision by NHS England in March 2024 to no longer prescribe puberty blockers routinely followed (source, source). According to a Danish review article, Denmark has also taken a more cautious approach to hormone treatment (source). In parts of the US there are bans for minors; the Supreme Court upheld the Tennessee one in June 2025 (source). See /international/comparison/.
In the Netherlands the Quality Standard Transgender Care Somatic (Kwaliteitsstandaard Transgenderzorg Somatisch, 2018) applies, which allows puberty suppression from Tanner stage 2 and cross-sex hormones from age 15 or 16 (source). According to an evaluation the minister sent to the House of Representatives in 2024, the standard is no longer entirely up to date in places and is being revised (source); the Zorginstituut has moved the deadline for the revised version to 30 September 2027 (source). In its advice of 30 June 2026 the Gezondheidsraad saw no reason to advise reorganising the care, but advised anchoring the due-care requirements more strongly in the revised standard (source). See /protocol/current-status-netherlands/.
In March 2024 Environmental Progress (founded by Michael Shellenberger) published leaked internal WPATH messages and a video of an internal panel discussion, with analysis by journalist Mia Hughes (source). Environmental Progress concludes from them that members know that children and adolescents cannot oversee the lifelong consequences of the treatment and that WPATH does not meet the standards of evidence-based medicine. That is Environmental Progress's reading: of the members it wrote to, one confirmed their own statements and another disputed the interpretation. See /evaluations/wpath-files-2024/.
According to the Cass Review, the Dutch Protocol approach was later extended to a broader group of adolescents who would not have met the criteria of the original Dutch study, and the current group is a different cohort from the group in earlier studies (source). Amsterdam UMC researchers (Arnoldussen et al., 2020) compared 1,072 adolescents referred between 2000 and 2016 and found, apart from the shift towards birth-registered girls, no trend in the intensity of gender dysphoria; they read this as an indication that in the early years only the tip of the iceberg reached the clinic (source). See /international/spread/.
Annelou de Vries (Amsterdam UMC), first author of the original studies, said to Zembla in October 2023 about research with a control group (translated): ‘That is not an option, you would withhold a treatment that you know is extremely important for a group’ (source). The Gezondheidsraad writes in 2026 that the strength of the evidence is low to very low: observational studies, mostly small and without an adequate control group, often with short follow-up (source). See /studies/methodological-criticism/.
English court case (Bell v Tavistock, 2020/2021) brought by Keira Bell against the Gender Identity Development Service (GIDS) of the Tavistock about whether minors are competent to consent to puberty blockers. On 1 December 2020 the High Court ruled that it was highly unlikely that a child of 13 or under could give competent consent and doubtful whether 14- and 15-year-olds could understand the long-term consequences (source). On 17 September 2021 the Court of Appeal set that ruling aside: it is for clinicians, not the court, to assess whether a child is competent to consent (source). See /debate/legal-cases/.
No. This site documents the Dutch Protocol as a scientific, clinical and policy phenomenon. Not medical, legal or policy advice. See /disclaimer/ and /methodology/.
See also
- Glossary — definitions of terms.
- People index — key figures.
- Comparison NL/UK/SE/FI/NO — policy per country.
- For parents · For clinicians · For journalists